Literature DB >> 1705834

Erythropoietin is both a mitogen and a survival factor.

J L Spivak1, T Pham, M Isaacs, W D Hankins.   

Abstract

Erythropoietin (Ep) regulates the proliferation and differentiation of erythroid progenitor cells, but whether it functions solely as a survival factor or also acts as a mitogen is unresolved. Because late erythroid progenitor cells (CFU-E) are largely in cell cycle, we examined this issue by using an Ep-dependent, murine erythroleukemia cell line, HCD-57. In the presence of human Ep and fetal calf serum, HCD-57 cells had a doubling time of approximately 24 hours, and during log-phase growth approximately 36% of the cells were in G1, 45% in S, and 19% in G2/M. With Ep deprivation, there was a gradual loss of viability and an arrest of proliferation with a 44% increase in the G0/G1 population, which could be reversed by reexposure to Ep even after 72 hours of hormone withdrawal. As little as 2 hours of exposure to Ep was sufficient to stimulate DNA synthesis, and the lag time for initiation of DNA synthesis after exposure to the hormone was approximately 10 hours as measured by either incorporation of labeled thymidine into DNA or cell cycle analysis by flow cytometry. RNA synthesis, by contrast, was initiated within 2 hours after exposure to Ep and did not require DNA synthesis. Total cell DNA content increased after exposure to Ep, indicating that it was acting as mitogen in HCD-57 cells. Ep was also able to stimulate DNA synthesis in the absence of serum as well as in its presence, indicating that the hormone could act as both a competence and a progression factor. Qualitative analysis of the integrity of HCD-57 DNA by electrophoresis in agar as well as direct measurement of DNA fragmentation after metabolic labeling with radioactive thymidine indicated that programmed cell death was occurring that could be reduced but not completely prevented by Ep. These data indicate that Ep acts as both a mitogen and a survival factor for HCD-57 cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705834

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Direct regulation of BCL-2 by FLI-1 is involved in the survival of FLI-1-transformed erythroblasts.

Authors:  Isabelle Lesault; Christine Tran Quang; Jon Frampton; Jacques Ghysdael
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

2.  Both the polycythemia- and anemia-inducing strains of Friend spleen focus-forming virus induce constitutive activation of the Raf-1/mitogen-activated protein kinase signal transduction pathway.

Authors:  K W Muszynski; T Ohashi; C Hanson; S K Ruscetti
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

3.  mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor.

Authors:  S Huang; S J Brandt
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

4.  Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models.

Authors:  M Mittelman; D Neumann; A Peled; P Kanter; N Haran-Ghera
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

5.  Changes in erythropoietin and haemoglobin concentrations in response to saturation diving.

Authors:  Dag Hofsø; Rune J Ulvik; Kåre Segadal; Arvid Hope; Einar Thorsen
Journal:  Eur J Appl Physiol       Date:  2005-07-08       Impact factor: 3.078

6.  Gene therapy for long-term expression of erythropoietin in rats.

Authors:  W R Osborne; N Ramesh; S Lau; M M Clowes; D C Dale; A W Clowes
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

7.  Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53.

Authors:  L L Kelley; W F Green; G G Hicks; M C Bondurant; M J Koury; H E Ruley
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

8.  Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin.

Authors:  Damien R Ashby; Daniel P Gale; Mark Busbridge; Kevin G Murphy; Neill D Duncan; Tom D Cairns; David H Taube; Stephen R Bloom; Frederick W K Tam; Richard Chapman; Patrick H Maxwell; Peter Choi
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

9.  Plasma erythropoietin levels in anaemic and non-anaemic patients with chronic liver diseases.

Authors:  Cosimo Marcello Bruno; Sergio Neri; Claudio Sciacca; Gaetano Bertino; Pietro Di Prima; Danila Cilio; Rinaldo Pellicano; Luciano Caruso; Raffaello Cristaldi
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

10.  The role of glucocorticoid receptor (GR) polymorphisms in human erythropoiesis.

Authors:  Lilian Varricchio; Anna Rita Migliaccio
Journal:  Am J Blood Res       Date:  2014-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.